Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01953692
Title A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

bone marrow cancer

multiple myeloma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries


No variant requirements are available.